Advanced search
Publication Cover
Statistical Theory and Related Fields Volume 5, 2021 - Issue 2: Special Issue on Experimental Design. Guest Editors: Xinwei Deng, Dept. of Statistics, College of Science, Virginia Tech, USA; Devon Lin, Dept. of Mathematics and Statistics, Queen‘s University, Canada.
Submit an article Journal homepage
641
Views
0
CrossRef citations to date
0
Altmetric
Articles

Target toxicity design for phase I dose-finding

Wenchuan Guoa Global Biometric Sciences, Bristol-Myers Squibb Company, Pennington, NJ, USA
&
Bob Zhongb Nektar Therapeutics, San Francisco, CA, USACorrespondence[email protected]
Pages 149-161 | Received 27 Dec 2018, Accepted 21 Jul 2020, Published online: 13 Aug 2020

References

  • Cheung, Y. K. (2013). dfcrm: Dose-finding by the continual reassessment method (Version, 0.2–2.1).
  • Cheung, Y. K., & Chappell, R. (2000). Sequential designs for phase I clinical trials with late-onset toxicities. Biometrics, 56(4), 1177–1182. https://doi.org/10.1111/j.0006-341X.2000.01177.x
  • Goodman, S. N., Zahurak, M. L., & Piantadosi, S. (1995). Some practical improvements in the continual reassessment method for phase I studies. Statistics in Medicine, 14(11), 1149–1161. https://doi.org/10.1002/(ISSN)1097-0258
  • Guo, W., Wang, S.-J., Yang, S., Lynn, H., & Ji, Y. (2017). A Bayesian interval dose-finding design addressing Ockham's razor: mTPI-2. Contemporary Clinical Trials, 58, 23–33. https://doi.org/10.1016/j.cct.2017.04.006
  • Ivanova, A., Flournoy, N., & Chung, Y. (2007). Cumulative cohort design for dose-finding. Journal of Statistical Planning and Inference, 137(7), 2316–2327. https://doi.org/10.1016/j.jspi.2006.07.009
  • Jennison, C., & Turnbull, B. W. (2000). Group sequential methods with applications to clinical trials. Chapman and Hall.
  • Ji, Y., Li, Y., & Nebiyou Bekele, B. (2007). Dose-finding in phase I clinical trials based on toxicity probability intervals. Clinical Trials, 4(3), 235–244. https://doi.org/10.1177/1740774507079442
  • Ji, Y., Liu, P., Li, Y., & Nebiyou Bekele, B. (2010). A modified toxicity probability interval method for dose-finding trials. Clinical Trials, 7(6), 653–663. https://doi.org/10.1177/1740774510382799
  • Ji, Y., & Yang, S. (2017). On the interval-based dose-finding designs. arXiv:1706.03277.
  • Lee, S. M., & Y. K. Cheung (2009). Model calibration in the continual reassessment method. Clinical Trials, 6(3), 227–238. https://doi.org/10.1177/1740774509105076
  • Leung, D. H.-Y., & Wang, Y.-G. (2001). Isotonic designs for phase I trials. Controlled Clinical Trials, 22(2), 126–138. https://doi.org/10.1016/s0197-2456(00)00132-x
  • Liu, S., & Yuan, Y. (2015). Bayesian optimal interval designs for phase I clinical trials. Journal of the Royal Statistical Society: Series C (Applied Statistics), 64(3), 507–523. https://doi.org/10.1111/rssc.2015.64.issue-3
  • O'Brien, P. C., & Fleming, T. R. (1979). A multiple testing procedure for clinical trials. Biometrics, 35(3), 549–556. https://doi.org/10.2307/2530245
  • O'Quigley, J., Pepe, M., & Fisher, L. (1990). Continual reassessment method: A practical design for phase 1 clinical trials in cancer. Biometrics, 46(1), 33–48. https://doi.org/10.2307/2531628
  • Paoletti, X., O'Quigley, J., & Maccario, J. (2004). Design efficiency in dose finding studies. Computational Statistics & Data Analysis, 45(2), 197–214. https://doi.org/10.1016/S0167-9473(02)00323-7
  • Reiner, E., Paoletti, X., & O'Quigley, J. (1999). Operating characteristics of the standard phase i clinical trial design. Computational Statistics & Data Analysis, 30(3), 303–315. https://doi.org/10.1016/S0167-9473(98)00095-4
  • Storer, B. E. (2001). An evaluation of phase I clinical trial designs in the continuous dose-response setting. Statistics in Medicine, 20(16), 2399–2408. https://doi.org/10.1002/(ISSN)1097-0258
  • Yuan, Y., Hess, K. R., Hilsenbeck, S. G., & Gilbert, M. R. (2016). Bayesian optimal interval design: A simple and well-performing design for phase I oncology trials. Clinical Cancer Research, 22(17), 4291–4301. https://doi.org/10.1158/1078-0432.CCR-16-0592

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.